| Literature DB >> 33805795 |
Carmine Izzo1,2, Monica Annunziata1,2, Giuseppe Melara1,2, Roberta Sciorio1,2, Marcello Dallio3, Mario Masarone1,2, Alessandro Federico3, Marcello Persico1,2.
Abstract
Many studies have shown that resveratrol has a lot of therapeutic effects on liver disorders. Its administration can significantly increase the survival rate after liver transplantation, reduce fat deposition and ischemia-induced necrosis and apoptosis in Wistar rats. Resveratrol can provide Liver protection against chemical, cholestatic, and alcohol-mediated damage. It can improve glucose metabolism and lipid profile, reduce liver fibrosis, and steatosis. Additionally, it is capable of altering the fatty acid composition of the liver cells. Resveratrol may be a potential treatment option for the management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant, and calorie-restricting effects. There are also studies that have evaluated the effect of resveratrol on lipid and liver enzyme profiles among patients with metabolic syndrome (MetS) and related disorders. Based on the extent of liver disease worldwide and the need to find new treatment possibilities, this review critically examines current in vitro and in vivo preclinical studies and human clinical studies related to liver protection.Entities:
Keywords: non-alcoholic fatty liver disease; nutraceutical; oxidative stress; resveratrol
Year: 2021 PMID: 33805795 PMCID: PMC7999728 DOI: 10.3390/nu13030933
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717